Study guide
4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
Key Takeaways Explain This Topic AI
The standardized Kirby-Bauer agar disk diffusion assay requires Mueller-Hinton agar at a depth of precisely 4 mm 4\text{ mm} 4 mm , an inoculum turbidity of 0.5 0.5 0.5 McFarland standard ( 1.5 × 10 8 CFU/mL 1.5 \times 10^8\text{ CFU/mL} 1.5 × 1 0 8 CFU/mL ), and incubation at 35 ∘ C 35^\circ\text{C} 3 5 ∘ C in ambient air.
The Minimum Inhibitory Concentration (MIC) is the lowest drug concentration visibly inhibiting bacterial growth, whereas the Minimum Bactericidal Concentration (MBC) kills ≥ 99.9 % \ge 99.9\% ≥ 99.9% of the original inoculum; an MBC / MIC ≥ 32 \text{MBC}/\text{MIC} \ge 32 MBC / MIC ≥ 32 defines antimicrobial tolerance.
Methicillin resistance in Staphylococcus aureus is mediated by the mecA gene encoding altered PBP2a, and is detected phenotypically with highest clinical sensitivity using a 30 μ g 30\ \mu\text{g} 30 μ g cefoxitin disk screen.
Inducible macrolide-lincosamide-streptogramin B ( i M L S B iMLS_B i M L S B ) resistance mediated by the erm gene is detected via the D-zone test: erythromycin-induced blunting of the clindamycin zone into a 'D' shape mandates reporting clindamycin as resistant.
Last updated: October 2026
Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
The emergence and global dissemination of antimicrobial resistance among pathogenic bacteria represent one of the most critical challenges in clinical medicine. In the clinical microbiology laboratory, standardized antimicrobial susceptibility testing (AST) guides targeted patient therapy and tracks multi-drug-resistant (MDR) phenotypes. The Clinical and Laboratory Standards Institute (CLSI) establishes standardized parameters that govern media formulation, inoculum standardization, incubation conditions, and interpretive breakpoints. Mastery of AST methodologies, technical troubleshooting, and resistance mechanisms is heavily weighted on the MTLE.
- 1. Antimicrobial Susceptibility Testing Methodologies ┌──────────────────────────────────────────────┐
- │ Antimicrobial Susceptibility Methods │
- └──────────────────────┬───────────────────────┘
- │
- ┌───────────────────────────────────────┼──────────────────────────────────────┐
- ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ Kirby-Bauer │ │Broth Dilution│ │E-Test / Grad.│
- │Disk Diffusion│ │ (MIC & MBC) │ │ Diffusion │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │
- Mueller-Hinton Agar • 2-fold serial dilutions • Plastic reagent strip with
- Agar depth: EXACTLY 4 mm in microtiter broth predefined exponential drug
- pH: 7.2 to 7.4 • MIC: Lowest concentration concentration gradient
- 0.5 McFarland inoculum visibly inhibiting growth • Direct quantitative MIC
- (1.5 x 10^8 CFU/mL) • MBC: Lowest concentration read where ellipse
- Incubation: 35°C in killing ≥99.9% inoculum intersects strip scale
- ambient air for 16-18 hr • Tolerance: MBC/MIC ≥ 32
- Kirby-Bauer Agar Disk Diffusion Method
Standardized according to CLSI document M02:
Standard Plating Medium : Mueller-Hinton Agar (MHA) . MHA demonstrates excellent batch-to-batch reproducibility, low concentrations of sulfonamide inhibitors (thymidine and thymine), supports the growth of non-fastidious aerobes, and features controlled divalent cation concentrations ( C a 2 + , M g 2 + Ca^{2+}, Mg^{2+} C a 2 + , M g 2 + ). Fastidious organisms require supplementation: Streptococcus pneumoniae and other streptococci are tested on MHA supplemented with 5 % 5\% 5% defibrinated sheep blood (MHA-F) .
Standard Agar Depth : The depth of MHA in Petri dishes must be precisely 4 mm 4\text{ mm} 4 mm (acceptable range: 3.5 to 4.5 mm 3.5\text{ to }4.5\text{ mm} 3.5 to 4.5 mm ; approximately 25 to 30 mL 25\text{ to }30\text{ mL} 25 to 30 mL for a 100 mm 100\text{ mm} 100 mm plate, 60 to 70 mL 60\text{ to }70\text{ mL} 60 to 70 mL for a 150 mm 150\text{ mm} 150 mm plate).
Medium pH : The pH must be within 7.2 to 7.4 7.2\text{ to }7.4 7.2 to 7.4 measured at room temperature ( 25 ∘ C 25^\circ\text{C} 2 5 ∘ C ).
Inoculum Standardization ( 0.5 McFarland 0.5\text{ McFarland} 0.5 McFarland ) : Bacterial colonies from an 18 – 24 hour 18\text{--}24\text{ hour} 18 – 24 hour agar plate are suspended in sterile saline or broth to match the turbidity of a 0.5 McFarland standard 0.5\text{ McFarland standard} 0.5 McFarland standard . Chemically, this standard is prepared by mixing 0.5 mL 0.5\text{ mL} 0.5 mL of 0.048 M B a C l 2 0.048\text{ M }BaCl_2 0.048 M B a C l 2 ( 1.175 % w/v B a C l 2 ⋅ 2 H 2 O 1.175\%\text{ w/v }BaCl_2 \cdot 2H_2O 1.175% w/v B a C l 2 ⋅ 2 H 2 O ) with 99.5 mL 99.5\text{ mL} 99.5 mL of 0.18 M H 2 S O 4 0.18\text{ M }H_2SO_4 0.18 M H 2 S O 4 ( 1 % v/v 1\%\text{ v/v} 1% v/v ), producing a fine barium sulfate ( B a S O 4 BaSO_4 B a S O 4 ) precipitate. Its spectrophotometric absorbance at 625 nm 625\text{ nm} 625 nm is 0.08 to 0.13 0.08\text{ to }0.13 0.08 to 0.13 , corresponding to an approximate bacterial suspension density of 1.5 × 10 8 CFU/mL 1.5 \times 10^8\text{ CFU/mL} 1.5 × 1 0 8 CFU/mL .
Inoculation Procedure & the 15-Minute Rule : A sterile cotton swab is dipped into the standardized suspension, rotated firmly against the inner tube wall above the liquid level to expel excess moisture, and swabbed over the entire MHA surface in three planes ( 60 ∘ 60^\circ 6 0 ∘ rotations), finishing with a rim sweep. Plates must be inoculated within 15 minutes of suspension preparation; antimicrobial disks must be applied within 15 minutes of inoculation; and plates must be placed into the incubator within 15 minutes of disk deposition.
Disk Spacing : Disks must be spaced ≥ 24 mm \ge 24\text{ mm} ≥ 24 mm apart center-to-center; a maximum of 12 disks may be placed on a 150 mm 150\text{ mm} 150 mm plate, or 5 disks on a 100 mm 100\text{ mm} 100 mm plate.
Incubation Parameters : Plates are inverted and incubated at 35 ± 2 ∘ C 35\pm 2^\circ\text{C} 35 ± 2 ∘ C in ambient air for 16 to 18 hours (24 hours for vancomycin and oxacillin against staphylococci and enterococci). Incubation in C O 2 CO_2 C O 2 is strictly prohibited for routine testing because dissolved C O 2 CO_2 C O 2 generates carbonic acid, lowering surface pH and altering antimicrobial activity.
Measurement and Interpretation : Zones of complete inhibition are measured to the nearest whole millimeter ( m m mm mm ) across the underside of the plate against a non-reflecting black background. Results are categorized as Susceptible (S) , Intermediate (I) , or Resistant (R) based on CLSI M100 breakpoint tables.
Dilution Susceptibility Testing (MIC and MBC)
Broth Microdilution : Performed in 96-well plastic microtiter trays containing two-fold serial dilutions of antimicrobials (e.g., 0.25 , 0.5 , 1 , 2 , 4 , 8 , 16 , 32 , 64 μ g/mL 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64\ \mu\text{g/mL} 0.25 , 0.5 , 1 , 2 , 4 , 8 , 16 , 32 , 64 μ g/mL ) in cation-adjusted Mueller-Hinton broth (CAMHB). Inoculated to achieve a final bacterial concentration of 5 × 10 5 CFU/mL 5 \times 10^5\text{ CFU/mL} 5 × 1 0 5 CFU/mL .
Minimum Inhibitory Concentration (MIC) : The lowest concentration of an antimicrobial agent (in μ g/mL \mu\text{g/mL} μ g/mL ) that completely prevents visible in vitro bacterial growth after 16 to 20 hours 16\text{ to }20\text{ hours} 16 to 20 hours of incubation.
Minimum Bactericidal Concentration (MBC) : Determined by subculturing a fixed volume (e.g., 10 μ L 10\ \mu\text{L} 10 μ L ) from all clear microtiter wells showing no visible turbidity onto antibiotic-free agar plates. The MBC is the lowest antimicrobial concentration that kills ≥ 99.9 % \ge 99.9\% ≥ 99.9% ( 3 log 10 3\log_{10} 3 lo g 10 reduction) of the original bacterial inoculum.
Antimicrobial Tolerance : An organism is defined as tolerant when the MBC / MIC ≥ 32 \text{MBC} / \text{MIC} \ge 32 MBC / MIC ≥ 32 . A tolerant pathogen is inhibited by standard concentrations but requires lethal doses far exceeding achievable clinical levels (e.g., Enterococcus faecalis or S. aureus in infective endocarditis treated with cell-wall active monotherapy).
Gradient Diffusion Method (E-Test)
Utilizes a plastic reagent strip impregnated with a continuous, predefined exponential gradient of dried antimicrobial agent spanning 15 two-fold dilutions. When placed onto an inoculated agar lawn, the antimicrobial diffuses immediately, generating a symmetrical, teardrop-shaped elliptical zone of inhibition. The quantitative MIC is read directly where the edge of the inhibition ellipse intersects the calibrated numerical scale printed on the strip face .
2. Technical Troubleshooting and Quality Control Errors in Kirby-Bauer
Adherence to CLSI standardization eliminates systematic testing errors:
Technical Variable Deviation from Standard Effect on Zone of Inhibition Clinical Consequence & Mechanism
Agar Depth Too thin ( < 4 mm <4\text{ mm} < 4 mm ) Falsely enlarged zones False Susceptibility : Decreased agar thickness promotes rapid lateral horizontal diffusion of drug with minimal vertical diffusion, creating larger zones.
Agar Depth Too thick ( > 4 mm >4\text{ mm} > 4 mm ) Falsely decreased zones False Resistance : Increased downward vertical diffusion drains antibiotic from the surface, restricting lateral horizontal spread.
Inoculum Density Too heavy ( > 0.5 McFarland >0.5\text{ McFarland} > 0.5 McFarland ) Falsely decreased zones False Resistance : Excessive bacterial mass overwhelms diffusing antibiotic, producing smaller zones.
Inoculum Density Too light ( < 0.5 McFarland <0.5\text{ McFarland} < 0.5 McFarland ) Falsely enlarged zones False Susceptibility : Sparse bacterial lawn is readily inhibited by sub-inhibitory drug concentrations.
Divalent Cations Excess C a 2 + Ca^{2+} C a 2 + and M g 2 + Mg^{2+} M g 2 + Falsely decreased zones for aminoglycosides False Resistance : Divalent cations competitively block aminoglycoside binding to outer membrane lipopolysaccharide of Pseudomonas aeruginosa .
Divalent Cations Deficient C a 2 + Ca^{2+} C a 2 + and M g 2 + Mg^{2+} M g 2 + Falsely enlarged zones for aminoglycosides False Susceptibility : Insufficient cation membrane stabilization enhances aminoglycoside entry into P. aeruginosa .
Thymidine / Thymine Excess in MHA medium Falsely decreased zones (inner haze) False Resistance : Bacteria utilize exogenous thymidine/thymine from medium, bypassing sulfonamide and trimethoprim folate biosynthesis inhibition.
Incubation Atmosphere Incubation in C O 2 CO_2 C O 2 incubator Altered zone sizes Carbonic acid lowers agar surface pH: decreases activity of aminoglycosides, macrolides, and clindamycin (smaller zones); increases tetracycline activity (larger zones).
3. Major Bacterial Resistance Mechanisms and Specialized Phenotypic Detection ┌────────────────────────────────────────────────────────┐
- │ Major Bacterial Resistance Mechanisms │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌───────────────────┬──────────────────┴──────────────────┬───────────────────┐
- ▼ ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ ESBL │ │ CRE │ │ MRSA │ │ iMLSB / erm │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │ │
- TEM, SHV, CTX-M • KPC, NDM, VIM • mecA gene encodes • Erythromycin
- Hydrolyzes 3rd/4th • Hydrolyzes PBP2a (low beta- induces 23S rRNA
- gen cephalosporins carbapenems lactam affinity) methylase
- Clavulanate • mCIM positive • 30 µg Cefoxitin • D-Test: Blunting of
- synergy ≥5 mm (E. coli growth) screen: ≤21 mm clindamycin zone
- confirms ESBL • eCIM: MBL zinc confirms MRSA mandates reporting
chelation Clindamycin RESIST.
Extended-Spectrum β \beta β -Lactamases (ESBL)
Molecular Mechanisms : Plasmid-encoded Class A serine β \beta β -lactamases (CTX-M, TEM, and SHV variants) found in Enterobacterales, most frequently Escherichia coli , Klebsiella pneumoniae , Klebsiella oxytoca , and Proteus mirabilis .
Resistance Spectrum : Hydrolyze all penicillins, all cephalosporin generations (including 3rd- and 4th-generation: ceftriaxone, cefotaxime, ceftazidime, cefepime), and monobactams (aztreonam). They do NOT hydrolyze cephamycins (cefoxitin, cefotetan) or carbapenems, and are inhibited in vitro by β \beta β -lactamase inhibitors ( clavulanic acid , sulbactam, tazobactam).
Phenotypic Confirmatory Test (CLSI Combined Disk Method) : Ceftazidime ( 30 μ g 30\ \mu\text{g} 30 μ g ) and cefotaxime ( 30 μ g 30\ \mu\text{g} 30 μ g ) disks are tested alone and in combination with clavulanic acid ( 10 μ g 10\ \mu\text{g} 10 μ g ) on MHA. An increase of ≥ 5 mm \mathbf{\ge 5\text{ mm}} ≥ 5 mm in zone of inhibition diameter for either antimicrobial agent tested in combination with clavulanate compared to the zone of the agent alone confirms an ESBL producer.
Carbapenem-Resistant Enterobacterales (CRE)
Molecular Mechanisms : Production of carbapenemase enzymes capable of hydrolyzing carbapenems (ertapenem, meropenem, imipenem) as well as almost all β \beta β -lactams. Classified by Ambler scheme:
Class A : Klebsiella pneumoniae carbapenemase ( KPC ); serine carbapenemase inhibited by avibactam and vaborbactam.
Class B Metallo- β \beta β -Lactamases (MBL) : NDM (New Delhi metallo- β \beta β -lactamase), VIM , IMP ; require zinc ( Z n 2 + Zn^{2+} Z n 2 + ) at active site, inhibited by metal chelators (EDTA), refractory to avibactam.
Class D : OXA-48-like carbapenemases; weak carbapenemases that do not hydrolyze 3rd-gen cephalosporins unless paired with an ESBL.
Phenotypic Detection (mCIM and eCIM) :
Modified Carbapenem Inactivation Method (mCIM) : A 10 μ g 10\ \mu\text{g} 10 μ g meropenem disk is incubated in a suspension of the test organism for 4 hours, then placed onto a lawn of susceptible E. coli ATCC 25922. If the test isolate produces carbapenemase, meropenem is hydrolyzed; E. coli grows up to the disk (zone 6 – 15 mm 6\text{--}15\text{ mm} 6 – 15 mm , positive mCIM).
EDTA-modified CIM (eCIM) : Testing the isolate simultaneously in broth containing EDTA. If EDTA chelates zinc and restores meropenem activity (zone increase ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm compared to mCIM), a metallo- β \beta β -lactamase is confirmed.
Methicillin-Resistant Staphylococcus aureus (MRSA)
Molecular Mechanism : Mediated by acquisition of the m e c A mecA m ec A gene (or m e c C mecC m ec C ) integrated on the mobile Staphylococcal Cassette Chromosome mec ( SCCmec ). The m e c A mecA m ec A gene encodes an altered transpeptidase called Penicillin-Binding Protein 2a (PBP2a) ( 78 kDa 78\text{ kDa} 78 kDa ), which possesses an exceptionally low binding affinity for virtually all β \beta β -lactam antibiotics. Strains are clinically resistant to all penicillins, cephalosporins (except 5th-generation anti-MRSA cephalosporins like ceftaroline), carbapenems, and β \beta β -lactamase inhibitor combinations.
Phenotypic Cefoxitin Disk Screen : The CLSI recommends a 30 μ g Cefoxitin disk 30\ \mu\text{g}\text{ Cefoxitin disk} 30 μ g Cefoxitin disk on MHA at 35 ∘ C 35^\circ\text{C} 3 5 ∘ C (read after 18 hours). Cefoxitin is a potent inducer of m e c A mecA m ec A -mediated PBP2a expression and produces sharper zone endpoints than oxacillin. A zone diameter of ≤ 21 mm \le 21\text{ mm} ≤ 21 mm indicates m e c A mecA m ec A -positive MRSA ( ≥ 22 mm \ge 22\text{ mm} ≥ 22 mm is methicillin-susceptible S. aureus , MSSA).
Oxacillin Salt Agar Screen : MHA containing 6 μ g/mL 6\ \mu\text{g/mL} 6 μ g/mL oxacillin and 4 % NaCl 4\%\text{ NaCl} 4% NaCl ; inoculated and incubated at 35 ∘ C 35^\circ\text{C} 3 5 ∘ C for 24 hours. Any growth ( ≥ 1 \ge 1 ≥ 1 colony) confirms oxacillin/methicillin resistance.
Gold Standard Confirmation : Molecular PCR detection of the m e c A mecA m ec A gene or latex agglutination assays detecting PBP2a protein.
Vancomycin-Resistant Enterococci (VRE)
Molecular Mechanism : Acquired plasmid-mediated operons ( v a n A vanA v an A , v a n B vanB v an B ) reprogram cell wall peptidoglycan biosynthesis. The terminal pentapeptide target D-Alanyl-D-Alanine (D-Ala-D-Ala) is substituted with D-Alanyl-D-Lactate (D-Ala-D-Lac) , reducing vancomycin binding affinity by 1,000-fold.
v a n A vanA v an A : High-level inducible resistance to both vancomycin (MIC ≥ 64 μ g/mL \ge 64\ \mu\text{g/mL} ≥ 64 μ g/mL ) and teicoplanin (MIC ≥ 16 μ g/mL \ge 16\ \mu\text{g/mL} ≥ 16 μ g/mL ); primarily in Enterococcus faecium .
v a n B vanB v an B : Variable resistance to vancomycin (MIC 4 to ≥ 1024 μ g/mL 4\text{ to }\ge 1024\ \mu\text{g/mL} 4 to ≥ 1024 μ g/mL ), but remains susceptible to teicoplanin.
v a n C vanC v an C (Intrinsic Resistance) : Chromosomally encoded in Enterococcus gallinarum (motile) and Enterococcus casseliflavus (motile, yellow pigment) . Synthesizes terminal D-Alanyl-D-Serine (D-Ala-D-Ser) , conferring low-level, non-transferable vancomycin resistance (MIC 4 – 16 μ g/mL 4\text{--}16\ \mu\text{g/mL} 4 – 16 μ g/mL ; teicoplanin susceptible).
Screening : Brain Heart Infusion (BHI) agar screen with 6 μ g/mL 6\ \mu\text{g/mL} 6 μ g/mL vancomycin; growth of > 1 >1 > 1 colony after 24 hours at 35 ∘ C 35^\circ\text{C} 3 5 ∘ C indicates resistance.
Inducible Macrolide-Lincosamide-Streptogramin B ( i M L S B iMLS_B i M L S B ) Resistance and the D-Test
Mechanisms in Staphylococci and Streptococci :
Efflux Pump ( m s r A msrA m sr A gene) : Active macrolide-specific efflux pump. Confers resistance to 14- and 15-membered macrolides (erythromycin) only; lincosamides (clindamycin) remain fully active ( E -R , C -S E\text{-R}, C\text{-S} E -R , C -S ). Clindamycin therapy is clinically safe.
Ribosomal Methylation ( e r m erm er m gene) : Erythromycin ribosome methylase dimethylates adenine residue A2058 in 23S rRNA, blocking binding of macrolides, lincosamides, and streptogramin B.
The D-Test Principle : The e r m erm er m gene can be expressed constitutively ( c M L S B cMLS_B c M L S B , resistant to both drugs) or inducibly ( i M L S B iMLS_B i M L S B ). In i M L S B iMLS_B i M L S B , erythromycin is a strong inducer of methylase translation, whereas clindamycin is an extremely weak inducer. In standard isolated testing, an i M L S B iMLS_B i M L S B strain tests Erythromycin-Resistant and Clindamycin-Susceptible .
Testing Procedure : An erythromycin disk ( 15 μ g 15\ \mu\text{g} 15 μ g ) and clindamycin disk ( 2 μ g 2\ \mu\text{g} 2 μ g ) are placed 15 to 26 mm 15\text{ to }26\text{ mm} 15 to 26 mm apart center-to-center on an MHA plate inoculated with the test isolate.
Interpretation and Clinical Reporting : Erythromycin diffuses toward the clindamycin disk, inducing methylase synthesis in adjacent bacteria. This produces a flattened or blunted zone of inhibition around clindamycin adjacent to the erythromycin disk, creating a distinct letter "D" shape .
Clinical Rule : An isolate with a positive D-test MUST be reported as Clindamycin-Resistant ( R R R ) , because administration of clindamycin in vivo selects for high-frequency constitutive mutants, leading to clinical treatment failure.